STRATA Skin Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

STRATA Skin Sciences wird ein Gewinn- und Umsatzwachstum von 35.5% bzw. 2.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 38.9% pro Jahr wachsen soll.

Wichtige Informationen

39.7%

Wachstumsrate der Gewinne

47.8%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.5%
Wachstumsrate der Einnahmen	7.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	19 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Aug 18

Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

Aug 07

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Jun 07

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

Mar 19

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Dec 31

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Nov 03

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

Jul 04

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Apr 18

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Jan 14

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

Aug 10

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

Jul 25

What Type Of Returns Would STRATA Skin Sciences'(NASDAQ:SSKN) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 09

Reflecting on STRATA Skin Sciences' (NASDAQ:SSKN) Share Price Returns Over The Last Five Years

Nov 24

STRATA Skin Sciences EPS in-line, beats on revenue

Nov 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:SSKN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	40	-2	N/A	7	1
12/31/2025	34	-6	N/A	3	2
12/31/2024	33	-7	N/A	0	1
6/30/2024	33	-8	-3	-1	N/A
3/31/2024	33	-11	-4	-1	N/A
12/31/2023	33	-11	-6	-1	N/A
9/30/2023	35	-7	-6	-1	N/A
6/30/2023	36	-7	-6	0	N/A
3/31/2023	37	-6	-6	-1	N/A
12/31/2022	36	-6	-5	-1	N/A
9/30/2022	35	-6	-4	0	N/A
6/30/2022	33	-6	-3	1	N/A
3/31/2022	31	-3	-3	1	N/A
12/31/2021	30	-3	-2	2	N/A
9/30/2021	28	-2	-2	1	N/A
6/30/2021	26	-3	-2	1	N/A
3/31/2021	22	-6	-1	2	N/A
12/31/2020	23	-4	0	2	N/A
9/30/2020	25	-4	N/A	3	N/A
6/30/2020	27	-4	0	3	N/A
3/31/2020	31	-3	0	2	N/A
12/31/2019	32	-4	-1	2	N/A
9/30/2019	31	-3	0	2	N/A
6/30/2019	31	-3	2	3	N/A
3/31/2019	31	-3	1	3	N/A
12/31/2018	30	-4	1	3	N/A
9/30/2018	31	-9	2	4	N/A
6/30/2018	30	-22	1	2	N/A
3/31/2018	31	-21	N/A	3	N/A
12/31/2017	32	-22	N/A	4	N/A
9/30/2017	30	-18	N/A	4	N/A
6/30/2017	31	-6	N/A	4	N/A
3/31/2017	30	-4	N/A	3	N/A
12/31/2016	31	-3	N/A	0	N/A
9/30/2016	33	-3	N/A	-1	N/A
6/30/2016	33	-14	N/A	-3	N/A
3/31/2016	26	-22	N/A	-5	N/A
12/31/2015	18	-28	N/A	-7	N/A
9/30/2015	9	-34	N/A	-10	N/A
6/30/2015	1	-24	N/A	-12	N/A
3/31/2015	1	-15	N/A	-14	N/A
12/31/2014	1	-16	N/A	-18	N/A
9/30/2014	1	-14	N/A	-19	N/A
6/30/2014	1	-19	N/A	-20	N/A
3/31/2014	0	-27	N/A	-20	N/A
12/31/2013	1	-26	N/A	-19	N/A
9/30/2013	1	-27	N/A	-21	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SSKN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SSKN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SSKN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SSKNDie Einnahmen des Unternehmens (2.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: SSKNDie Einnahmen des Unternehmens (2.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SSKN in 3 Jahren voraussichtlich hoch sein wird

STRATA Skin Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 64%

Consensus EPS estimates fall by 33%

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Price target decreased by 11% to US$3.60

Consensus EPS estimates fall by 32%

Recent updates

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 29, 2024

Consensus estimates of losses per share improve by 64%

Investors Don't See Light At End Of STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Tunnel And Push Stock Down 30%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

STRATA Skin Sciences, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Is STRATA Skin Sciences (NASDAQ:SSKN) Weighed On By Its Debt Load?

New minor risk - Shareholder dilution

STRATA Skin Sciences Announces Approval of XTRAC Momentum 1.0 Device in Japan

President recently bought US$60k worth of stock

STRATA Skin Sciences Regains Compliance with Nasdaq Rule 5550(a)(2)

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Shares Lagging The Industry But So Is The Business

Consensus EPS estimates fall by 33%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

STRATA Skin Sciences, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 15%

No longer forecast to breakeven

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt In A Risky Way?

STRATA Skin Sciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

STRATA Skin Sciences, Inc.'s (NASDAQ:SSKN) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Strata Skin Sciences, Inc. Promotes Shmuel Gov to the Position of Chief Operating Officer

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 11% to US$3.60

STRATA Skin Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Health Check: How Prudently Does STRATA Skin Sciences (NASDAQ:SSKN) Use Debt?

Less than half of directors are independent

STRATA Skin Sciences, Inc. Announces Management Change

STRATA Skin Sciences, Inc., Annual General Meeting, Oct 26, 2023

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Forecast breakeven date moved forward to 2024

STRATA Skin Sciences, Inc. to Report Q2, 2023 Results on Aug 09, 2023

We Think STRATA Skin Sciences (NASDAQ:SSKN) Has A Fair Chunk Of Debt

STRATA Skin Sciences, Inc. Announces Board Changes

STRATA Skin Sciences, Inc. Announces First Patients Treated in TheraClear®X Clinical Study for Acne

First quarter 2023 earnings: EPS misses analyst expectations

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Stock Rockets 26% But Many Are Still Ignoring The Company

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues exceed analyst expectations

STRATA Skin Sciences Announces TheraClearX Product Demonstration at Inaugural Winter Clinical Conference

STRATA Skin Sciences, Inc. Revises Revenue Guidance for the Full Year 2022

STRATA Skin Sciences, Inc. Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference

Is STRATA Skin Sciences (NASDAQ:SSKN) Using Debt Sensibly?

Consensus estimates of losses per share improve by 12%

Forecast to breakeven in 2024

STRATA Skin Sciences, Inc. Reiterates Earnings Guidance for the Year 2022

STRATA Skin Sciences Receives Non-Compliance Letter from NASDAQ

STRATA Skin Sciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

STRATA Skin Sciences, Inc. Provides Revenue Guidance Full Year 2022

STRATA Skin Sciences GAAP EPS of -$0.05 in-line, revenue of $9.1M beats by $0.96M

STRATA Skin Sciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Strata Skin Sciences Announces U.S. Commercial Launch of Theraclear®X Acne Therapy System

Strata Skin stock soars ~18% after hours on U.S. commercial launch of acne treatment

STRATA Skin Sciences, Inc., Annual General Meeting, Jun 22, 2022

Consensus forecasts updated

STRATA Skin Sciences, Inc. Names Michael E. Goodman as Head of International Sales

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

STRATA Skin Sciences, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$4.30

STRATA Skin Sciences, Inc. Appoints Patricia S. Walker to Its Board of Director

STRATA Skin Sciences Announces Commercial Launch of XTRAC Momentum 1.0 and First Installation in the U.S

STRATA Skin Sciences, Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2021

Third quarter 2021 earnings released: US$0.015 loss per share (vs US$0.037 loss in 3Q 2020)

Price target increased to US$4.80

Independent Director recently bought US$104k worth of stock

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.05 loss in 2Q 2020)